Study: Hydroxychloroquine Helps Coronavirus Patients Survive

26
A pharmacist shows a box of antimalarial tablets called "Plaquenil", on March 23, 2020, in Rennes, western France, on the seventh day of a strict lockdown in France to stop the spread of COVID-19 (novel coronavirus). - On the evening of March 17, 2020, the pharmaceutical group Sanofi which works on a vaccine against the novel coronavirus, said itself ready to offer to the French authorities millions of doses of the antimalarial Plaquenil, which could potentially treat 300,000 patients, after trials deemed "promising" from patients infected with Covid-19. (Photo by Damien Meyer / AFP) / RESTRICTED TO EDITORIAL USE (Photo by DAMIEN MEYER/AFP via Getty Images)

WASHINGTON (Newsmax) – A new study reveals that the hydroxychloroquine doubled the survival rate of patients hospitalized with COVID-19.

Doctors at Henry Ford Health System in southeast Michigan said that 26% of patients who did not receive the antimalarial drug died, compared to 13% of patients who received hydroxychloroquine during their stay in the hospital.

The team published their findings in the International Journal of Infectious Diseases, adding that patients who were given hydroxychloroquine alone did even better than the ones who received this drug along with azithromycin, according to CNN.

Other studies have shown no benefits of taking hydroxychloroquine for COVID-19, and some said that it may increase the risk for cardiovascular complications. President Donald Trump told reporters in May that he was taking the drug and called it a possible “game changer,” according to ABC News.

The Food and Drug Administration revoked its emergency use authorization for hydroxychloroquine on June 15, and trials around the world that were sponsored by the World Health Organization and the National Institutes of Health were stopped, according to CNN.

“Our results do differ from some other studies,” Dr. Marcus Zervos, division head of infectious diseases at Henry Ford, said. “What we think was important in ours is that patients were treated early. For hydroxychloroquine to have a benefit, it needs to begin before the patients begin to suffer some of the severe immune reactions that we have with COVID-19,” he added.

A French study published in Science Direct posted similar results. Researchers noted: “We believe there is an urgency to evaluate the effectiveness of this potentially life-saving therapeutic strategy at a larger scale.”


Listen to the VINnews podcast on:

iTunes | Spotify | Google Podcasts | Stitcher | Podbean | Amazon

Follow VosIzNeias For Breaking News Updates




26 Comments
Most Voted
Newest Oldest
Inline Feedbacks
View all comments